25th week of 2012 patent applcation highlights part 59 |
Patent application number | Title | Published |
20120157455 | Compounds And Compositions For Treating Cancer - The invention relates to compounds and composition for the treatment and prevention of cancer. The invention also covers all diseases that may be treated by selective modulation of levels of reactive oxygen species in diseased cells versus normal cells. Methods for the preparation and administration of such compositions are also disclosed. | 2012-06-21 |
20120157456 | SUBSTITUTED AMINOPROPENYL PIPERIDINE OR MORPHOLINE DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE - This invention comprises the novel compounds of formula (I) | 2012-06-21 |
20120157457 | COMPOSITIONS AND METHODS FOR INDUCING NEURONAL DIFFERENTIATION - The present invention provides compositions and methods for inducing neuronal cell differentiation. | 2012-06-21 |
20120157458 | IMIDAZOTRIAZINONE COMPOUNDS - The present invention provides imidazotriazinone compounds which are inhibitors of phosphodiesterase 9. The present invention further provides processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of PDE9 associated diseases or disorders in mammals, including humans. | 2012-06-21 |
20120157459 | NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE | 2012-06-21 |
20120157460 | TETRAHYDRO-AZACARBOLINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USES THEREOF - The present invention relates to tetrahydro-azacarboline derivatives of formula (I): | 2012-06-21 |
20120157461 | Indolyl-Substituted Pyrazino-Quinolines and Their Use for the Treatment of Cancer - There is provided compounds of formula I, wherein the wedged bonds, R | 2012-06-21 |
20120157462 | Hydroxamic acid derivatives of aniline useful as therapeutic agents for treating anthrax poisoning - Compounds having the formula | 2012-06-21 |
20120157463 | CHROMONE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATIONS - The present invention relates to chromone derivatives, their preparation, their pharmaceutical compositions and their application as D3 dopaminergic ligands as a medicament for disorders of the central nervous system. | 2012-06-21 |
20120157464 | USE OF AZABICYCLOALKYL DERIVATIVES OR PYRROLIDINE-2-ONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF ATAXIA - The invention concerns the use of azabicycloalkyl derivatives or pyrrolidine-2-one derivatives for the treatment, prevention or delay of progression of ataxia. | 2012-06-21 |
20120157465 | DNA METHYLATION INHIBITORS - A number of DNA methylation inhibitors are described. The DNA methylation inhibitors were identified using a two-component enhanced green fluorescent protein reporter system to screen a compound library containing procainamide derivatives. The DNA methylation inhibitors can be used for cancer therapy and prevention. | 2012-06-21 |
20120157466 | HETEROCYCLIC COMPOUNDS WITH CXCR3 ANTAGONIST ACTIVITY - The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1 or Formula 5: | 2012-06-21 |
20120157467 | COMPOSITION AND USE FOR PHOSPHODIESTERASE INHIBITORS - Compositions and methods for enhancing the aesthetic appearance of the lip or lips of a human achieved by applying to the surface of the lip a composition containing a phosphodiesterase inhibitor, preferably a pyrazolopyrimidinone such as sildenafil or its citrate salt. | 2012-06-21 |
20120157468 | PLK INHIBITOR SALTS - The present invention relates to novel crystalline, water-soluble salts of a plk inhibitor. Such crystal salts are for example L-tartrate, succinate, phosphate, mesylate, maleate, L-malate, hydrochloride, fumarate (half mole of counterion), fumarate, citrate (half mole of counterion), benzenesulfonate and L-aspartate (half mole of counterion). New crystal forms of the base as well as solvates and hydrates of such new salt forms, a process for their preparation, their utility in therapy and to the pharmaceutical compositions containing them are also claimed and described in the present application. | 2012-06-21 |
20120157469 | PIPERAZINONE-SUBSTITUTED TETRAHYDRO-CARBOLINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USES THEREOF - The present invention relates to piperazinone-substituted tetrahydro-carboline derivatives of formula (I): | 2012-06-21 |
20120157470 | SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT - Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}-sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer. | 2012-06-21 |
20120157471 | BENZIMIDAZOLE DERIVATIVES - The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R | 2012-06-21 |
20120157472 | METHOD FOR TREATING COLORECTAL CANCER - The present invention relates to a method of treating patients suffering from colorectal cancer characterized by coadministration of BIBF 1120 and BIBW 2992, wherein in said method BIBF 1120 is administered according to a continuous daily regimen and BIBW 2992 is administered according to a weekly alternating on-off regimen, pharmaceutical compositions and kits suitable for this method as well as their preparation. | 2012-06-21 |
20120157473 | THERAPEUTIC METHODS AND COMPOUNDS - The invention provides diketopiperazines of formula I. The invention also provides pharmaceutical compositions comprising the diketopiperazines, or pharmaceutically-acceptable salts or prodrugs thereof, as the active ingredient. The invention further provides therapeutic treatments that utilize the diketopiperazines of formula I, including inhibition of a proliferative disease or condition, inhibition of angiogenesis, treatment of an angiogenic disease or condition, treatment of cancer and precancerous conditions, treatment of a fibrotic disorder, treatment of a viral infection, treatment of an Akt-mediated disease or condition, inhibition of the production, release or both of matrix metalloproteinase-9, and inhibition of Akt activation. | 2012-06-21 |
20120157474 | Methods of Identifying and Using General or Alternative Splicing Inhibitors - The present invention is based on the discovery of a cell-based system to identify novel modulators of splicing or splicing dependent processes. The cell-based system of the present invention utilizes a fast and highly sensitive reporter, that responds to defects in the splicing machinery itself and is sensitive to changes in the signals that regulate splicing dependent processes such as those that modulate the EJC, splicing-dependent export, localization or translation efficiency. The present invention further uses the cell-based screen to identify several small molecules that modulate both constitutive and alternative splicing. Accordingly, the present invention includes general or alternative splicing inhibitors identified using the assay described herein. The present invention also provides methods of treating a subject having a condition associated with aberrant target RNA expression. The present invention further details a kit that may be directed to specifically detecting a general or alternative splicing inhibitor of the invention. | 2012-06-21 |
20120157475 | Combination Preparation Against Vertigo - The use of cinnarizine and dimenhydrinate or their physiologically compatible salts in combination is described for the treatment of vertigo of any genesis. | 2012-06-21 |
20120157476 | OXIME COMPOUNDS - The present invention relates to compounds of the formula | 2012-06-21 |
20120157477 | REVERSAL OF L-DOPA-INDUCED DYSKINESIA BY NEURONAL NICOTINIC RECEPTOR LIGANDS - The present invention includes methods, uses, and compounds for treating or preventing L-dopa-induced dyskinesias. | 2012-06-21 |
20120157478 | Hair Care Compositions and Methods to Improve Hair Appearance - Hair care compositions and methods that can increase the appearance of healthier hair by increasing the appearance of thicker and fuller hair, longer hair, and/or delayed emergence of gray hair. Such compositions can be applied to any areas where healthier hair appearance is desired, such as the scalp or face. | 2012-06-21 |
20120157479 | 3-HYDROXYPYRROLIDINE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE - The present invention relates to 3-hydroxypyrrolidine compounds of the general formula (I) which are inhibitors of 5′-methylthioadenosine phosphorylase or 5′-methylthioadenosine nucleosidase. The invention also relates to the use of these compounds in the treatment of diseases or conditions in which it is desirable to inhibit 5′-methylthioadenosine phosphorylase or 5′-methylthioadenosine nucleosidase including cancer, and to pharmaceutical compositions containing the compounds. | 2012-06-21 |
20120157480 | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors - The present invention provides diagnostic and prognostic methods for predicting the effectiveness of treatment of a cancer patient with an EGFR kinase inhibitor. Methods are provided for predicting the sensitivity of tumor cell growth to inhibition by an EGFR kinase inhibitor, comprising assessing whether the tumor cell has undergone an epithelial to mesenchymal transition (EMT), by determining the expression level of epithelial and/or mesenchymal biomarkers, wherein tumor cells that have undergone an EMT are substantially less sensitive to inhibition by EGFR kinase inhibitors. Improved methods for treating cancer patients with EGFR kinase inhibitors that incorporate the above methodology are also provided. Additionally, methods are provided for the identification of new biomarkers that are predictive of responsiveness of tumors to EGFR kinase inhibitors. Furthermore, methods for the identification of agents that restore the sensitivity of tumor cells that have undergone EMT to inhibition by EGFR kinase inhibitors are also provided. | 2012-06-21 |
20120157481 | TRICYCLIC PYRIMIDINE DERIVATIVES AS WNT ANTAGONISTS - The present invention relates to compounds having the general formula (I) with the definitions of X1-X3, Y1, Y2, L1, R1 and R2 given below and/or solvates, hydrates, esters and pharmaceutically acceptable salts thereof. Furthermore, the invention relates to the use of said compounds for modulating of the Wnt signalling pathway activity and their use as a medicament, preferably for the treatment of cancer. | 2012-06-21 |
20120157482 | COMPOUNDS AND METHODS - Disclosed are compounds having the formula: | 2012-06-21 |
20120157483 | Method for Treating Liver Diseases of Various Origins - The invention relates to medicine, in particular to gastroenterology, and lies in the field of treatment of liver diseases of various origins. For this purpose, the hepatoprotective agent that is introduced to the patient is embodied as derivatives of bis(2-thio-4,6-dioxo-1,2,3,4,5,6-hexahydropyrimidine-5-yl)arylmethanes: | 2012-06-21 |
20120157484 | TRYPTOPHAN HYDROXYLASE INHIBITORS - Compounds of formulae I and II are disclosed, as well as compositions comprising them and methods of their use to treat, prevent and manage serotonin-mediated diseases and disorders: | 2012-06-21 |
20120157485 | SYNERGISTIC FUNGICIDAL INTERACTIONS OF 5-FLUOROCYTOSINE AND OTHER FUNGICIDES - A fungicidal composition containing a fungicidally effective amount of a) a compound of Formula I and (b) at least one fungicide selected from the group consisting of myclobutanil, fenbuconazole, difenoconazole, trifloxystrobin, pentiopyrad, fluopyram, boscalid, mancozeb, and pyrimethanil provides synergistic control of selected fungi. | 2012-06-21 |
20120157486 | SYNERGISTIC FUNGICIDAL INTERACTIONS OF AMINOPYRIMIDINES AND OTHER FUNGICIDES - A fungicidal composition containing a fungicidally effective amount of a) a compound of Formula I and (b) at least one fungicide selected from the group consisting of myclobutanil, fenbuconazole, difenoconazole, trifloxystrobin, penthiopyrad, fluopyram, boscalid, mancozeb, pyrimethanil, and bixafen provides synergistic control of selected fungi. | 2012-06-21 |
20120157487 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS - The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors. | 2012-06-21 |
20120157488 | ARYL-AND HETEROARYLCARBONYL DERIVATIVES OF HEXAHYDROINDENOPYRIDINE AND OCTAHYDROBENZOQUINOLINE - The present invention relates to compounds defined by formula I | 2012-06-21 |
20120157489 | TREATMENT OF ENDOMETRIOSIS - A pharmaceutical composition comprising quinagolide for the treatment and/or prevention of endometriosis. | 2012-06-21 |
20120157490 | N-BIARYLAMIDES - The invention relates to N-biarylamides useful for the prophylaxis and/or treatment of impairments of perception, concentration, learning and/or memory, and to processes for preparing them, and pharmaceutical compositions containing them. | 2012-06-21 |
20120157491 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS - Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided. | 2012-06-21 |
20120157492 | ANTIBIOTIC DRUG - This invention relates to a malic acid salt of (3S,5R)-7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid. Also disclosed is a method of treating bacterial infection by an effective amount of this salt. | 2012-06-21 |
20120157493 | Antifungal and Antiparasitic Indoloquinoline Derivatives - “An indoloquinoline wherein the quarternary N-5 atom is a straight C(1-5) chain, a branched C(1-5) chain, a heteroatom chain, a straight chain substituted terminally by a cycloalkyl or aromatic ring, a branched chain substituted terminally by a cycloalkyl or aromatic ring, a heteroatom chain substituted terminally by a cycloalkyl or aromatic ring; the 10 position is N—R | 2012-06-21 |
20120157494 | ISOINDOLYL COMPOUNDS - Compounds of the formula I: | 2012-06-21 |
20120157495 | BENZIMIDAZOLE DERIVATIVES - The present invention relates to a compound of the Formula I | 2012-06-21 |
20120157496 | STABILIZED AND PRESERVED KETOTIFEN OPHTHALMIC COMPOSITIONS - Ophthalmic compositions comprising ketotifen and a source of hydrogen peroxide providing an amount of hydrogen peroxide of from about 0.001 to about 0.1% (w/v) of hydrogen peroxide, and methods for the treatment and prevention of allergic conjunctivitis using these compositions are provided herein. | 2012-06-21 |
20120157497 | COMPOUNDS HAVING ANALGESIC AND/OR IMMUNOSTIMULANT ACTIVITY - The compounds shown by their structural formulas in the specification have analgesic and or immunostimulant activity in mammals. | 2012-06-21 |
20120157498 | SUBSTITUTED ENAMINOCARBONYL COMPOUNDS - The present invention relates to novel substituted enaminocarbonyl compounds, to processes for their preparation and to their use for controlling animal pests, especially arthropods, in particular insects. | 2012-06-21 |
20120157499 | DELIVERY OF AN ACTIVE DRUG TO THE POSTERIOR PART OF THE EYE VIA SUBCONJUNCTIVAL OR PERIOCULAR DELIVERY OF A PRODRUG - The present invention relates to method of sustained-delivery of an active drug to a posterior part of an eye of a mammal to treat or prevent a disease or condition affecting said mammal, wherein said disease or condition can be treated or prevented by the action of said active drug upon said posterior part of the eye, comprising administering an effective amount of an ester prodrug of the active drug subconjunctivally or periocularly. Preferably, the active drug is more than about 10 times as active as the prodrug. Other aspects of this invention deal with the treatment of certain diseases by the periocular or subconjunctival delivery of an ester prodrug, and certain pharmaceutical products containing ester prodrugs for periocular or subconjunctival administration. | 2012-06-21 |
20120157500 | JAK INHIBITION BLOCKS RNA INTERFERENCE ASSOCIATED TOXICITIES - The instant invention provides a method for treating patients by administering a JAK inhibitor. The instant invention provides a method for treating patients by administering a JAK inhibitor wherein the JAK inhibitor is a JAK2 inhibitor. The instant invention provides a method for treating patients by administering a JAK inhibitor wherein the JAK inhibitor is selected from selected from Jak2-IA, AG490, Pyridone 6, WP1066, LS104, TG101209, TG101348, CP690,550, CP352,664, INCB18424, WHI-P154, CMP6, SB1518, XL019, CEP-701, INCB20, AUH-6-96 and AZ960. | 2012-06-21 |
20120157501 | ISOKETAL SCAVENGERS AND MITIGATION OF DISORDERS INVOLVING OXIDATIVE INJURY - A method of treating and/or preventing oxidative damage, comprising administering an effective IsoK/NeuroK adduct formation suppressing amount of a phenolic amine compound and/or pyridoxamine or pyridoxamine analog, including embodiments where the phenolic compound is at least one of a pyridoxamine, salicylamine, tyrosine compound or an analog thereof. | 2012-06-21 |
20120157502 | PHENANTHRENONE COMPOUNDS, COMPOSITIONS AND METHODS - The present invention is directed to compounds of Formula I: | 2012-06-21 |
20120157503 | NICOTINIC ACID COMPOSITIONS FOR TREATING HYPERLIPIDEMIA AND RELATED METHODS THEREFOR - An orally administered antihyperlipidemia composition according to the present invention includes from about 250 to about 3000 parts by weight of nicotinic acid, and from about 5 to about 50 parts by weight of hydroxypropyl methylcellulose. Also, a method of treating hyperlipidemia in a hyper lipidemic having a substantially periodic physiological loss of consciousness, includes the steps of forming a composition having an effective antihyperlipidemic amount of nicotinic acid and a time release sustaining amount of a swelling agent. The method also includes the step of orally administering the composition to the hyperlipidemic once per day “nocturnally,” that is in the evening or at night. | 2012-06-21 |
20120157504 | New Process - The present invention relates to a process for the preparation of S-[2-[1-(2-ethylbutyl)cyclohexylcarbonylamino]-phenyl]2-methylthiopropionate which is useful as a pharmaceutically active compound. | 2012-06-21 |
20120157505 | ORAL FORMULATIONS OF BENDAMUSTINE - The present invention is directed to oral formulations of bendamustine, and its pharmaceutically acceptable salts, methods of use thereof, and methods of treatment comprising them. | 2012-06-21 |
20120157506 | Novel Imidazole-2-Benzamide Compounds Useful for the Treatment of Osteoarthritis - The present invention provides compounds of the formula below | 2012-06-21 |
20120157507 | USP47 Inhibtors and Methods to Induce Apoptosis - The present invention relates to USP47 (ubiquitin specific protease 47) inhibitors and methods for inducing apoptosis or cell death in a target cell. In certain embodiments, the invention relates to methods and kits to screen for related agents that induce apoptosis. Additionally, the invention relates to assays for screening compounds capable of acting as USP47 inhibitors. | 2012-06-21 |
20120157508 | TARGETING EN2, PAX2, AND/OR DEFB1 FOR TREATMENT OF PROSTATE CONDITIONS - The present invention relates to methods and compositions for treating a prostate condition in a subject. The method comprises administering to the subject a subject effective amount of a pharmaceutical composition having a first agent that inhibits EN2 expression and/or EN2 activity and a second agent that inhibits PAX2 expression and/or PAX2 activity. The pharmaceutical composition may further comprise a third agent that enhances DEFB1 expression or activity. | 2012-06-21 |
20120157509 | GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR siRNA - The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to cell in vivo. The pharmacokinetic modulator improve in vivo targeting compared to the targeting ligand alone. Targeting ligand-pharmacokinetic modulator targeting moiety targeted RNAi polynucleotides can be administered in vivo alone or together with co-targeted delivery polymers. | 2012-06-21 |
20120157510 | Controlling The Potential Of Primate Neural Stem Cells By Regulating Pax6 - A transcription factor both necessary and sufficient for human neuroectoderm specification, Pax6, as well as applications thereof, is disclosed. | 2012-06-21 |
20120157511 | 5' PHOSPHATE MIMICS - The present invention provides nucleosides and oligonucleotides comprising a 5′ phosphate mimics of formula (IVc) or (Vc). One aspect of the present invention relates to modified nucleosides and oligonucleotides comprising such dinucleotide of formula (Ia). Another aspect of the invention relates to a method of inhibiting the expression of a gene in call, the method comprising (a) contacting an oligonucleotide of the invention with the cell; and (b) maintaining the cell from step (a) for a time sufficient to obtain degradation of the mRNA of the target gene. | 2012-06-21 |
20120157512 | Preventing and Curing Beneficial Insect Diseases Via Plant Transcribed Molecules - Methods and compositions for transforming plants to express polynucleotides capable of gene silencing gene expression in pathogens of beneficial insets such as IAPV, | 2012-06-21 |
20120157513 | Small Peptide Expression System in Mammalian Cells - The present invention is directed to a delivery vector for transferring a small peptide coding sequence to a cell for expression of the small peptide coding sequence within the cell. The delivery vector comprises a secretory signal sequence; a sequence encoding a carrier protein operatively associated with the secretory signal sequence; a sequence encoding a cleavage site operatively associated with the sequence encoding a carrier protein; and a sequence encoding a small peptide operatively associated with the sequence encoding a cleavage site. | 2012-06-21 |
20120157514 | OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS - Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided. | 2012-06-21 |
20120157515 | Methods and compositions for the treatment of "Burning Feet Syndrome" - Disclosed herein Methods and composition for the treatment of an individual with “Burning Feet Syndrome”. Included are the manner and process of making the composition, administration, uses, and effective therapeutic amounts of Pantothenic acid and Alpha-lipoic acid with no adverse side effects. The composition can be used to prophylax (prevent), treat acute or chronic symptoms caused by “Burning Feet Syndrome”. In combination with certain adjuvants, carriers, vehicles and delivery systems to improve the efficacy. | 2012-06-21 |
20120157516 | NOVEL THIOPHENE COMPOUNDS FOR USE IN THERAPY - The present invention relates to novel substituted thiophene derivatives useful in therapy of diseases related to misfolded and aggregated proteins. | 2012-06-21 |
20120157517 | PHARMACEUTICAL SOLUTION OF TAXANES COMPRISING PH REGULATOR AND PREPARATION METHOD THEREOF - A pharmaceutical solution of taxanes, its preparation method, a composition comprising said solution and its pharmaceutical combination package are disclosed. Said pharmaceutical solution comprises taxanes, a pH regulator and a solvent, wherein the pH regulator is a water-soluble acid. | 2012-06-21 |
20120157518 | Sublingual Spray Formulation Comprising Dihydroartemesinin - The invention provides pharmaceutical compositions for the treatment of neoplastic diseases, fluke infestations and Lyme disease, comprising compounds capable of providing dihydroartemesinin and a medium chain triglyceride formulated for transmucosal sublingual, buccal or nasal delivery, especially by a spray. Also provided are delivery devices containing the compositions. | 2012-06-21 |
20120157519 | TELLERIUM-CONTAINING COMPOUNDS FOR TREATING VIRAL INFECTIONS - Tellurium-containing compounds identified for use in a method of treating, or prophylaxis against, a viral infection caused by an influenza virus, uses thereof and pharmaceutical kits and pharmaceutical corn positions comprising the same, are disclosed. The tellurium-containing compounds disclosed herein are suitable for co-administration with an antiviral agent. | 2012-06-21 |
20120157520 | DIOXANES DERIVED FROM REGROUPING CARBOHYDRATES AND C-GLYCOSIDES, PROCESS FOR OBTAINING SAME AND USES THEREOF - The present invention relates to compounds with a dioxane nucleus derived from carbohydrates and C-glucosides, process for obtaining same, to the use of such compounds as cytotoxic and antiproliferative agents and to the use thereof for producing a cancer treatment drug. | 2012-06-21 |
20120157521 | TREATMENT OF MACULAR DEGENERATION - The present invention relates generally to methods for treating macular degeneration, and in particular age-related macular degeneration, involving the use of specific benzofuran based compounds. | 2012-06-21 |
20120157522 | B. Anthracis Prevention and Treatment: Mutant B. Anthracis Lacking Luxs Activity and Furanone Inhibition of Growth, AI-2 Quorum Sensing, and Toxin Production - The present invention pertains to the discovery that | 2012-06-21 |
20120157523 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE - Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions comprising prodrugs of methyl hydrogen fumarate, and methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis are disclosed. | 2012-06-21 |
20120157524 | 3-METHANESULFONYLPROPIONITRILE FOR TREATING INFLAMMATION AND PAIN - The present invention relates to purified 3-methanesulfonylpropionitrile or a pharmaceutically acceptable salt thereof, and a method for preparing such compound. The compound has at least 90% (w/w) purity. The present invention is also directed to a pharmaceutical composition comprises the purified compound and a pharmaceutically acceptable carrier. The present invention is further directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering 3-methanesulfonylpropionitrile or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof. | 2012-06-21 |
20120157525 | TREATING ECZEMA AND/OR PSORIASIS - The treatment of humans or other mammals for eczema and/or psoriasis using dosage forms or compositions that include cetyl myristate alone or (in admixture or serially) both cetyl myristate and cetyl palmitate. | 2012-06-21 |
20120157526 | TREATMENT OF PORTAL HYPERTENSION AND RESTORATION OF LIVER FUNCTION USING L-ORNITHINE PHENYLACETATE - Disclosed herein are methods of treating and/or preventing portal hypertension and/or restoring liver function using L-ornithine phenylacetate. | 2012-06-21 |
20120157527 | COSMETIC USE OF A JASMONIC ACID DERIVATIVE FOR TREATING THE HAIR AND THE SCALP - The present invention relates to the cosmetic use of jasmonic acid derivatives of formula (I) | 2012-06-21 |
20120157528 | LEAVE-ON NONSOLID SKIN CONDITIONING COMPOSITIONS CONTAINING 12-HYDROXYSTEARIC ACID AND ETHOXYLATED HYDROGENATED CASTOR OIL - Leave-on non-solid skin conditioning compositions comprising 12-hydroxy stearic acid. Compositions contain 12HSA, yet have a relatively low viscosity, so are suitable for spreading on the skin, and are stable on storage and structurally reversible through temperature cycling. | 2012-06-21 |
20120157529 | Composition and Method for Prevention, Mitigation or Treatment of an Enteropathogenic Bacterial Infection - The present invention embraces the use of palmitoleic acid, or a derivative, mimetic, or extract containing the same, to decrease the expression of bacterial virulence factors thereby preventing, mitigating, or treating bacterial infection. | 2012-06-21 |
20120157530 | METHODS OF TREATING HYPERTRIGLYCERIDEMIA - In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. | 2012-06-21 |
20120157531 | COMPOSITIONS AND METHODS FOR LOWERING TRIGLYCERIDES - In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof. | 2012-06-21 |
20120157532 | Method Of Treating Or Preventing A Convulsive Disorder In A Patient In Need Thereof - The present invention relates to a method of treating or preventing a convulsive disorder in a patient in need thereof comprising administering said patient with a therapeutically effective amount of an active ingredient that induces a high level of extracellular GABA or increases GABA receptor activation once per day in the evening or at night. | 2012-06-21 |
20120157533 | Magnesium Compositions and Uses Thereof for Metabolic Disorders - A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound. A magnesium-counter ion composition described herein may be useful for any of a variety of applications provided herein, such as maintaining, enhancing, and/or improving health, nutrition, and/or another condition of a subject, and/or cognitive, learning, and/or memory function. A magnesium-counter ion composition provided herein may be useful for administration to a subject presenting magnesium deficiency, mild cognitive impairment, Alzheimer's disease, attention deficit hyperactivity disorder, ALS, Parkinson's disease, diabetes, migraine, anxiety disorder, mood disorder, and/or hypertension. A kit, method, and other associated technology are also provided. | 2012-06-21 |
20120157534 | COMPOSITIONS AND METHODS OF TREATMENT FOR INFLAMMATORY DISEASES - Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or large intestine and may involve deeper layers of the bowel wall. The present invention in a preferred embodiment is a combination of 5-aminosalicylic acid or 4-aminosalicylic acid and one or more antioxidants (e.g., N-acetylcysteine) for treating such inflammatory bowel diseases. | 2012-06-21 |
20120157535 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR DYSMENORRHEA - Disclosed is a prophylactic and/or therapeutic agent for dysmenorrhea and/or associated symptoms thereof. Specifically disclosed is a prophylactic and/or therapeutic agent for dysmenorrhea and/or associated symptoms thereof, which comprises tranilast as an active ingredient thereof. | 2012-06-21 |
20120157536 | COMPOSITION FOR TRANSDERMAL ADMINISTRATION OF NON-STEROIDAL ANTI-FLAMMATORY DRUG - This invention pertains to compositions and method for transdermal administration of non-steroidal anti-inflammatory and analgesic drugs (NSAID) for the treatment of inflammation and pain caused by conditions such as arthritis, degenerative joint disease, minor strains, pains, and contusions. This invention particularly relates to transdermal compositions comprising an NSAID, a bioadhesive graft copolymer, and a skin penetration enhancer, selected from pyrrolidone or its derivatives and dialkyl sulfoxides and combinations thereof. | 2012-06-21 |
20120157537 | NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau - Aminocyclohexane and aminoalkylcyclohexane compounds, which are systemically-active as NMDA receptor antagonists, are effective in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau, method of treating disorders resulting from or associated with abnormal hyperphosphorylation of microtubule associated protein tau, and pharmaceutical compositions comprising the same. | 2012-06-21 |
20120157538 | Compounds for the Inhibition of Herpes Viruses - 3D protein modeling and virtual screening of commercially-available compounds were performed to identify new inhibitors of the herpesvirus DNA polymerase, a key enzyme in the viral replication cycle. Two compounds (Nos 2 and 9) were particularly active against HSV-1 and HSV-2 strains and one compound (No 3) inhibited specifically cytomegalovirus (CMV) strains (overall hit rate of 25%). Some of the tested compounds inhibited wild-type viruses and strains resistant to current antiviral agents. New chemical entity derivatives of compound 2 with binding potential to the DNA polymerase retained an excellent activity against HSV-1, HSV-2 and VZV like the parental compound, as well against strains resistant to current antiviral agents. These non-nucleosidic herpesvirus DNA polymerase inhibitors with in vitro activity against drug-resistant clinical isolates warrant further pre-clinical studies. | 2012-06-21 |
20120157539 | NUCLEAR RECEPTOR BINDING AGENTS - The present invention relates to a novel class of selective estrogen receptor modulators (SERMs). The SERM compounds are applicable for use in the prevention and/or treatment of a variety of diseases and conditions including prevention and treatment of cancers such as prostate and breast cancer, osteoporosis, hormone-related diseases, hot flashes or vasomotor symptoms, neurological disorders, cardiovascular disease and obesity. | 2012-06-21 |
20120157540 | Disinfectant and Sanitizer Formulations - The present invention relates to disinfectant formulations containing: (i) an antimicrobial active agent selected from the group consisting of biguanides, monoguanides, and combinations thereof; (ii) a compound selected from the group consisting of a dialkyldimethyl ammonium salt, an alkyldimethylbenzyl ammonium salt, an alkyldimethyl(ethylbenzyl) ammonium salt, and combinations thereof wherein the formulation is free of sequestrants. The total amount of the component (i) and the component (ii) is from about 500 ppm to about 1000 ppm based on the weight of the disinfectant formulation, and the component (i) and the component (ii) are present in a range of weight ratios between about 1:1 and about 1:10. | 2012-06-21 |
20120157541 | SOLUBLE PHARMACEUTICAL FORMULATIONS OF N,N-DIAMINODIPHENYL SULFONE FOR OPTIMAL USE IN THE TREATMENT OF VARIOUS DISEASES - The present invention aims to demonstrate that a soluble pharmaceutical formulation can be prepared of N,N′-Diamino-diphenyl sulfone which is useful in the development of an ideal drug for use against cerebral infarction, epilepsy, traumatic spinal cord injury, cranio-encephalic trauma, leprosy, | 2012-06-21 |
20120157542 | METHOD TO ASSESS PROGNOSIS AND TO PREDICT THERAPEUTIC SUCCESS IN CANCER BY DETERMINING HORMONE RECEPTOR EXPRESSION LEVELS - The present invention is related to a method of classifying a sample of a patient who suffers from or being at risk of developing cancer, said method comprising the steps of determining in said sample from said patient, on a non protein basis, the expression level of at least one gene encoding for a hormone receptor selected from the group comprising estrogen receptor, progesterone receptor and/or androgen receptor in said sample; comparing the one or more expression level(s) determined with one or more expression level(s) of one or more reference genes, and classifying the sample of said patient from the outcome of the comparison into one of at least two classifications. | 2012-06-21 |
20120157543 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)-OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE - This disclosure concerns the discovery of (R,R)- and (R,S)-fenoterol analogues which are highly effective at binding β2-adrenergic receptors. Exemplary chemical structures for these analogues are provided. Also provided are pharmaceutical compositions including the disclosed (R,R)-fenoterol and fenoterol analogues, and methods of using such compounds and compositions for the treatment of cardiac disorders such as congestive heart failure and pulmonary disorders such as asthma or chronic obstructive pulmonary disease. | 2012-06-21 |
20120157544 | Process for the Preparation of O-Desmethyl Venlafaxine and Intermediate for Use Therein - The present invention relates to a compound of formula A, wherein R is alkyl. | 2012-06-21 |
20120157545 | METHODS FOR TREATING SKIN DISORDERS WITH TOPICAL NITROGEN MUSTARD COMPOSITIONS - Provided are methods for treating skin disorders comprising topically applying to the affected skin a composition comprising a nitrogen mustard or a pharmaceutically acceptable salt thereof. | 2012-06-21 |
20120157546 | Compositions Containing Aromatic Aldehydes and Their Use in Treatments - Disclosed are pharmaceutical and cosmetic compositions containing aromatic aldehyde compounds. Some of the disclosed compositions are useful as topical therapeutics for treating inflammatory dermatologic conditions. Some of the compositions are useful in transdermal and other systemic dose forms for treating other inflammatory conditions in mammals. | 2012-06-21 |
20120157547 | COMPOSITIONS AND APPLICATIONS OF CAROTENOIDS OF IMPROVED ABSORPTION AND BIOAVAILABILITY - Micro micellar form of carotenoids or xanthophylls, which show improved absorption and biovailability by living organisms, providing higher levels of carotenoids in the blood stream, and consequently are deposited at the target tissues at a faster rate, and more efficiently than crystalline carotenoids, which does not contain any crystal forms of carotenoids, and which are obtained as micro micelles after melting Lutein diacetate or Lutein dipropionate in their natural original lipid vegetable matrix, in the presence of lipids, phospholipids, fatty acids, emulsifiers and moisture, and are ingested in a dosage between 2 to 50 mg, to provide an absorption of the carotenoid solubilizate which is at least 20% above than that of crystalline carotenoids, and provides a macular pigment deposit which exceeds at least 10% of Macular Pigment Optical Density, than the deposition obtained by ingesting crystalline Lutein. Thus preventing tissue degeneration, UV light damage to skin and the retina, and in general to act as more effective and efficient antioxidants than when administered in crystalline form. | 2012-06-21 |
20120157548 | USE OF CYCLOALIPHATIC DIOLS AS BIOCIDES - Use of diols with a cycloaliphatic group as biocide. | 2012-06-21 |
20120157549 | METHODS OF PREVENTING, TREATING AND DIAGNOSING DISORDERS OF PROTEIN AGGREGATION - Disclosed are methods of preventing, treating, or diagnosing in a subject a disorder in protein folding or aggregation, or amyloid formation, deposition, accumulation, or persistence consisting of administering to said subject a pharmaceutically effective amount of inositol stereoisomers, enantiomers or derivatives thereof. | 2012-06-21 |
20120157550 | DRUG CARRIERS COMPRISING AMPHILPHILIC BLOCK COPOLYMERS - An aqueous composition comprises an amphiphilic block copolymer, having a hydrophilic block comprising pendant zwitterionic groups and a hydrophobic block, and a biologically active compound associated with the polymer. The polymer is preferably in the form of micelles, and preferably the biological active is a hydrophobic drug. The hydrophilic block is preferably formed from acrylic monomer including phosphorylcholine groups. The hydrophobic group is suitably formed from monomer which has groups which can be ionised at useful pH's, especially tertiary amine groups. Micelles may be formed by dissolving the block copolymer in aqueous solvent at a pH at which the amine groups are protonated then raising the pH to a value at which the amine groups are substantially deprotonated, whereupon micelles spontaneously form. The preformed micelles are then contacted with active, under conditions such that solubilisation of the active occurs. The active may be for tumour treatment. | 2012-06-21 |
20120157551 | Use of Polymers - The present invention relates to the use of branched addition copolymers possessing melt or solution viscosities lower than the linear polymer analogues of equivalent or greater weight average molecular weight, compositions comprising said copolymers, methods for their preparation, and he use of novel polymers per se in for example but not limited to solution formulations or melt formulations. | 2012-06-21 |
20120157552 | Novel concentrated inverse latex, process for preparing it and industrial use thereof - A composition in the form of a positive latex includes: a) 50-80 wt. % of at least one cross-linked, branched, or linear organic polymer (P), b) 5-10 wt. % of a water-in-oil (W/O) emulsifying system (S | 2012-06-21 |
20120157553 | Methods for Using Rebaudioside C as a Flavor Enhancer - The present invention is directed to the use of one or more rebaudioside C polymorphs, or stereoisomers thereof, to enhance the sweet taste of a flavoring, such as glucosylated steviol glycoside, rebaudioside A, ammoniated glycyrrhizin, neohespherdin dihydrochalcone or thaumatin. | 2012-06-21 |
20120157554 | MEDIUM OIL USED FOR A SYNTHESIS REACTION, PROCESS FOR PREPARING DIMETHYL ETHER AND PROCESS FOR PREPARING A MIXTURE OF DIMETHYL ETHER AND METHANOL - A medium oil to be used for a synthesis reaction in a slurry-bed reaction procedure. The medium oil has as a main component, a branched, saturated aliphatic hydrocarbon having 16 to 50 carbon atoms, 1 to 7 tertiary carbon atoms, 0 quaternary carbon atoms, and 1 to 16 carbon atoms in the branched chains bonded to the tertiary carbon atoms; and at least one of the tertiary carbon atoms is bonded to hydrocarbon chains with a chain length having 4 or more carbon atoms in three directions, wherein the synthesis reaction in the slurry-bed reaction procedure comprises producing an oxygen-containing organic compound from a raw gas containing carbon monoxide and hydrogen. | 2012-06-21 |